Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum Article

Full Text via DOI: 10.1007/s11239-022-02643-3 Web of Science: 000796798800002

Cited authors

  • Barnes GD, Burnett A, Allen A, Ansell J, Blumenstein M, Clark NP, Crowther M, Dager WE, Deitelzweig SB, Ellsworth S, Garcia D, Kaatz S, Raffini L, Rajasekhar A, Van Beek A, Minichiello T


  • Thromboembolism is a common and deadly consequence of COVID-19 infection for hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and early observational reports, expert consensus and guidance documents have strongly encouraged the use of prophylactic anticoagulation for patients hospitalized for COVID-19 infection. More recently, multiple clinical trials and larger observational studies have provided evidence for tailoring the approach to thromboprophylaxis for patients with COVID-19. This document provides updated guidance for the use of anticoagulant therapies in patients with COVID-19 from the Anticoagulation Forum, the leading North American organization of anticoagulation providers. We discuss ambulatory, in-hospital, and post-hospital thromboprophylaxis strategies as well as provide guidance for patients with thrombotic conditions who are considering COVID-19 vaccination.

Publication date

  • 2022

International Standard Serial Number (ISSN)

  • 0929-5305

Number of pages

  • 14